These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30508592)

  • 21. Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: A systematic review.
    Maglione MA; Raaen L; Chen C; Azhar G; Shahidinia N; Shen M; Maksabedian E; Shanman RM; Newberry S; Hempel S
    J Subst Abuse Treat; 2018 Jun; 89():28-51. PubMed ID: 29706172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are patients' goals in treatment associated with expected treatment outcomes? Findings from a mixed-methods study on outpatient pharmacological treatment for opioid use disorder.
    Rosic T; Naji L; Panesar B; Chai DB; Sanger N; Dennis BB; Marsh DC; Rieb L; Worster A; Thabane L; Samaan Z
    BMJ Open; 2021 Jan; 11(1):e044017. PubMed ID: 33436476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder.
    Nasser AF; Greenwald MK; Vince B; Fudala PJ; Twumasi-Ankrah P; Liu Y; Jones JP; Heidbreder C
    J Clin Psychopharmacol; 2016 Feb; 36(1):18-26. PubMed ID: 26650971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recovery Goals and Long-term Treatment Preference in Persons Who Engage in Nonmedical Opioid Use.
    Hay KR; Huhn AS; Tompkins DA; Dunn KE
    J Addict Med; 2019; 13(4):300-305. PubMed ID: 30633045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
    Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
    Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolonged-release opioid agonist therapy: qualitative study exploring patients' views of 1-week, 1-month, and 6-month buprenorphine formulations.
    Neale J; Tompkins CNE; Strang J
    Harm Reduct J; 2019 Apr; 16(1):25. PubMed ID: 30943990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.
    Daitch J; Frey ME; Silver D; Mitnick C; Daitch D; Pergolizzi J
    Pain Physician; 2012 Jul; 15(3 Suppl):ES59-66. PubMed ID: 22786462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug use, health and social outcomes of hard-to-treat heroin addicts receiving supervised injectable opiate treatment: secondary outcomes from the Randomized Injectable Opioid Treatment Trial (RIOTT).
    Metrebian N; Groshkova T; Hellier J; Charles V; Martin A; Forzisi L; Lintzeris N; Zador D; Williams H; Carnwath T; Mayet S; Strang J
    Addiction; 2015 Mar; 110(3):479-90. PubMed ID: 25251885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patterns and Quality of Buprenorphine Opioid Agonist Treatment in a Large Medicaid Program.
    Gordon AJ; Lo-Ciganic WH; Cochran G; Gellad WF; Cathers T; Kelley D; Donohue JM
    J Addict Med; 2015; 9(6):470-7. PubMed ID: 26517324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Pregnancy Recovery Center: A women-centered treatment program for pregnant and postpartum women with opioid use disorder.
    Krans EE; Bobby S; England M; Gedekoh RH; Chang JC; Maguire B; Genday P; English DH
    Addict Behav; 2018 Nov; 86():124-129. PubMed ID: 29884421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double-blind, placebo-controlled trial.
    Wang X; Jiang H; Zhao M; Li J; Gray F; Sheng L; Li Y; Li X; Ling W; Li W; Hao W
    Asia Pac Psychiatry; 2019 Mar; 11(1):e12344. PubMed ID: 30460781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychosocial intervention utilization and substance abuse treatment outcomes in a multisite sample of individuals who use opioids.
    Harvey LM; Fan W; Cano MÁ; Vaughan EL; Arbona C; Essa S; Sanchez H; de Dios MA
    J Subst Abuse Treat; 2020 May; 112():68-75. PubMed ID: 32199548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world evidence for a prescription digital therapeutic to treat opioid use disorder.
    Maricich YA; Xiong X; Gerwien R; Kuo A; Velez F; Imbert B; Boyer K; Luderer HF; Braun S; Williams K
    Curr Med Res Opin; 2021 Feb; 37(2):175-183. PubMed ID: 33140981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psycho-physiological response to pain among individuals with comorbid pain and opioid use disorder: Implications for patients with prolonged abstinence.
    Wachholtz A; Gonzalez G; Ziedonis D
    Am J Drug Alcohol Abuse; 2019; 45(5):495-505. PubMed ID: 31246117
    [No Abstract]   [Full Text] [Related]  

  • 35. Assessment of medication for opioid use disorder as delivered within the Vermont hub and spoke system.
    Rawson R; Cousins SJ; McCann M; Pearce R; Van Donsel A
    J Subst Abuse Treat; 2019 Feb; 97():84-90. PubMed ID: 30577904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial.
    Back SE; Payne RL; Wahlquist AH; Carter RE; Stroud Z; Haynes L; Hillhouse M; Brady KT; Ling W
    Am J Drug Alcohol Abuse; 2011 Sep; 37(5):313-23. PubMed ID: 21854273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cognitive Behavioral Therapy Improves Treatment Outcomes for Prescription Opioid Users in Primary Care Buprenorphine Treatment.
    Moore BA; Fiellin DA; Cutter CJ; Buono FD; Barry DT; Fiellin LE; O'Connor PG; Schottenfeld RS
    J Subst Abuse Treat; 2016 Dec; 71():54-57. PubMed ID: 27776678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions.
    Ling S; Mangaoil R; Cleverley K; Sproule B; Puts M
    Drug Alcohol Depend; 2019 Apr; 197():168-182. PubMed ID: 30831429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients.
    DiPaula BA; Menachery E
    J Am Pharm Assoc (2003); 2015; 55(2):187-92. PubMed ID: 25749264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single high-dose buprenorphine for opioid craving during withdrawal.
    Ahmadi J; Jahromi MS; Ghahremani D; London ED
    Trials; 2018 Dec; 19(1):675. PubMed ID: 30526648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.